Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease

Shanghai Jiao Tong University School of Medicine1 site in 1 country304 target enrollmentJune 2004

ConditionsType 2 Diabetes Coronary Artery Disease

InterventionsGlipizide Metformin

DrugsGlipizide Metformin

Overview

Phase: Phase 4
Intervention: Glipizide
Conditions: Type 2 Diabetes
Sponsor: Shanghai Jiao Tong University School of Medicine
Enrollment: 304
Locations: 1
Primary Endpoint: Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study

The end point of this study is:

follow up 3yr
recurrence of cardiovascular event
death caused by other reasons such as stroke, uremia, blindness and amputation

Registry

clinicaltrials.gov

Start Date

June 2004

End Date

July 2010

Last Updated

15 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shanghai Jiao Tong University School of Medicine

Eligibility Criteria

Inclusion Criteria

•Coronary heart disease
•Type 2 diabetes

Exclusion Criteria

•Severe organ dysfunction, psychopathy, infection, neutropenia
•Congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy

Arms & Interventions

metformin

Intervention: Glipizide

glipizide

Intervention: Metformin

Outcomes

Primary Outcomes

Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization